

Application No.: 10/777310

Case No.: 58232US004

AMENDMENTS TO THE CLAIMS

The following Listing of Claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1-20. (Canceled)

21. (Original) A pharmaceutical composition comprising a TLR8 agonist in combination with a pharmaceutically acceptable carrier.

22-29. (Canceled)

30. (New) The pharmaceutical composition of claim 21 wherein the TLR8 agonist is a substituted imidazoquinoline amine.

31. (New) The pharmaceutical composition of claim 21 wherein the TLR8 agonist is a tetrahydroimidazoquinoline amine.

32. (New) The pharmaceutical composition of claim 21 wherein the TLR8 agonist is an imidazopyridine amine.

33. (New) The pharmaceutical composition of claim 21 wherein the TLR8 agonist is a 1,2-bridged imidazoquinoline amine.

34. (New) The pharmaceutical composition of claim 21 wherein the TLR8 agonist is a 6,7-fused cycloalkylimidazopyridine amine.

35. (New) The pharmaceutical composition of claim 21 wherein the TLR8 agonist is an imidazonaphthyridine amine.

Application No.: 10/777310

Case No.: 58232US004

36. (New) The pharmaceutical composition of claim 21 wherein the TLR8 agonist is a tetrahydroimidazonaphthyridine amine.
37. (New) The pharmaceutical composition of claim 21 wherein the TLR8 agonist is an oxazoloquinoline amine.
38. (New) The pharmaceutical composition of claim 21 wherein the TLR8 agonist is a thiazoloquinoline amine.
39. (New) The pharmaceutical composition of claim 21 wherein the TLR8 agonist is an oxazolopyridine amine.
40. (New) The pharmaceutical composition of claim 21 wherein the TLR8 agonist is a thiazolopyridine amine.
41. (New) The pharmaceutical composition of claim 21 wherein the TLR8 agonist is an oxazonaphthyridine amine.
42. (New) The pharmaceutical composition of claim 21 wherein the TLR8 agonist is a thiazolonaphthyridine amine.
43. (New) The pharmaceutical composition of claim 21 wherein the TLR8 agonist is a 6-, 7-, 8-, or 9-aryl or heteroaryl substituted imidazoquinoline amine.
44. (New) The pharmaceutical composition of claim 21 wherein the TLR8 agonist is a 1*H*-imidazo dimer fused to a pyridine amine, quinoline amine, tetrahydroquinoline amine, naphthyridine amine, or tetrahydronaphthyridine amine.